-
biomarkers for
bevacizumab efficacy are not yet known.
Current studies show that
VEGFs are not the only
promoters of angiogenesis. In particular, FGF2 and HGF...
-
VEGF receptors (VEGFRs) are
receptors for
vascular endothelial growth factor (
VEGF).
There are
three main
subtypes of VEGFR,
numbered 1, 2 and 3. Depending...
-
stimulated by
VEGF: sunitinib, sorafenib, axitinib, and
pazopanib (some of
these therapies target VEGF receptors rather than the
VEGFs). Both antibody-based...
-
endothelial growth factor B also
known as
VEGF-B is a
protein that, in humans, is
encoded by the
VEGF-B gene.
VEGF-B is a
growth factor that
belongs to the...
-
circulating VEGFs and acts like a "
VEGF trap". It
thereby inhibits the
activity of the
vascular endothelial growth factor subtypes VEGF-A and
VEGF-B, as well...
-
pegaptanib and aflibercept.
These anti-
VEGF agents may be
administered monthly or adaptively. For
adaptive anti-
VEGF treatment, two
approaches are conventionally...
- and are
collectively referred to as PVFs (PDGF/
VEGF-like
growth factors. The
comparison of
human VEGFs with
these PVFs
allows conclusions on the structure...
-
Vascular endothelial growth factor A (
VEGF-A) is a
protein that in
humans is
encoded by the
VEGFA gene. This gene is a
member of the platelet-derived growth...
- a
VEGF-trap. The
company was
founded by CEO
Leonard Schleifer and
scientist George Yancopoulos in 1988.
Regeneron has
developed aflibercept, a
VEGF inhibitor...
- most
widely used
VEGF pathway inhibitor on the
market today is Bevacizumab.
Bevacizumab binds to
VEGF and
inhibits it from
binding to
VEGF receptors. Angiogenesis...
